Skip to main content
. 2021 Jun 18;53(2):395–403. doi: 10.3947/ic.2021.0304

Table 4. Comparison of combination therapy versus monotherapy.

Outcome Number of studies Study name (clinical trial or intervention) Sample size Estimated effect size
3.1 Viral load Change (Ct value) from baseline to day 11 vs. placebo 1 Gottlieb2021 (BLAZE-1) bamlanivimab/etesevimab vs. bamlanivimab 418 MD = −0.61 [−1.11, −0.11]

Ct, cycle threshold of the reverse-transcriptase–polymerase-chain-reaction assay; MD, mean difference; RR, risk ratio.